Company intelligence / Profile preview

Alsachim

Illkirch-Graffenstaden, Grand Est, Francealsachim.com ↗

Ownership: Private
Employees: ~53
Development stage: Commercial

Overview

Alsachim supplies stable isotope-labeled compounds and reference standards globally for analytical chemistry and life science research. It also develops Therapeutic Drug Monitoring devices to support hospitals and clinical labs. The company was acquired by Shimadzu Corporation and merged into Shimadzu Chemistry & Diagnostics in 2024–2025.

Therapeutic areas: Other
Modalities: Small moleculeDevice
Industry: Metabolite Diagnostics

Partnerships

Extensive collaborations with hospitals, CROs/CMOs/biotech/pharma companies worldwidenow part of the global Shimadzu network

Beyond the preview

Go deeper on Alsachim.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alsachim.

Explore the full profile